By vgreene, 27 January, 2020 If baseline LDL-C ≥220 w/ on-tx LDL-C ≥130, age 40-75 yo: Consider add-on PCSK9i1
By vgreene, 27 January, 2020 If heterozygous FH w/ on-tx LDL-C ≥100, age 30-75 yo: Consider add-on PCSKi1
By vgreene, 27 January, 2020 If on-tx LDL-C ≥100 in pt w/ multiple risk factors:1 Consider add-on PCSK9i1
By vgreene, 27 January, 2020 75 yo Factor risk reduction potential adverse effects drug interactions health status pt preference in statin decision if already tolerating high intensity statin reasonable to continue per ACC AHA 1 AACE states that many older people benefit from LDL C l
By vgreene, 27 January, 2020 20 75 yo High intensity statin atorvastatin 40 or 80 mg rosuvastatin 20 or 40 mg If LDL C darr
By vgreene, 27 January, 2020 18-19 yo w/ persistent LDL-C ≥190: If inadequate response to 3- to 6-mo lifestyle trial, statin reasonable per ACC/AHA1
By vgreene, 27 January, 2020 Prompt high intensity max tolerated statin for primary severe hypercholesterolemia per ACC AHA 1 AACE specifies target LDL C based on risk2 and FH 2 ADA specifies recommendations for pts w DM 3 Heart healthy lifestyle1 3
By vgreene, 27 January, 2020 Mod intensity 30 49 LDL C lowering atorvastatin 10 or 20 mg rosuvastatin 5 or 10 mg simvastatin 20 40 mg pravastatin 40 or 80 mg lovastatin 40 or 80 mg fluvastatin XL 80 mg fluvastatin 40 mg bid pitavastatin 1 4 mg